Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2007;100:1650-1658
Published online before print May 10, 2007, doi: 10.1161/CIRCRESAHA.107.153494
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
100/11/1650    most recent
CIRCRESAHA.107.153494v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Womack, M. D.
Right arrow Articles by Barrett-Jolley, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Womack, M. D.
Right arrow Articles by Barrett-Jolley, R.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Cell signalling/signal transduction
Right arrow Ion channels/membrane transport
Right arrow Autonomic, reflex, and neurohumoral control of circulation
Right arrow Receptor pharmacology
(Circulation Research. 2007;100:1650.)
© 2007 American Heart Association, Inc.


Integrative Physiology

Substance P Targets Sympathetic Control Neurons in the Paraventricular Nucleus

Matthew D. Womack, Richard Morris, Thomas C. Gent, Richard Barrett-Jolley

From the Veterinary Sciences Faculty, Brownlow Hill, University of Liverpool, UK.

Correspondence to Dr Richard Barrett-Jolley, University of Liverpool, Department of Preclinical Veterinary Sciences, Faculty of Veterinary Sciences, Liverpool L69 7ZJ, United Kingdom. E-mail RBJ{at}LIV.AC.UK

The paraventricular nucleus (PVN) contains spinally-projecting neurons implicated in fine-tuning the cardiovascular system. In vivo activity of "presympathetic" parvocellular neurons is suppressed by tonic inhibition from GABA-ergic inputs, inhibition of which increases sympathetic pressor activity and heart rate. Targeting of this specific neuronal population could potentially limit elevations of heart rate and blood pressure associated with disease. Here we show, for the first time, that "presympathetic" PVN neurons are disinhibited by the neuropeptide substance P (SP) acting via tachykinin NK1 receptor inhibition of GABAA currents. Application of SP to the paraventricular nucleus of rats increases heart rate and blood pressure. In in vitro brain slice experiments, in the presence of GABA, 1µmol/L SP increased action current frequency by a factor of 2.7±0.6 (n=5, P≤0.05, ANOVA). Furthermore, 1µmol/L SP inhibited GABAA currents by 70±8% (n=8, P≤0.005 paired t test). These effects were abolished by NK1 antagonists, but not NK2 and NK3 antagonists. GABAA inhibition was not reproduced by NK2 or NK3 agonists. The inhibition of parvocellular GABAA currents by SP was also abolished by a protein kinase C (PKC) inhibitor peptide and mimicked by application of phorbol-12-myristate-13-acetate (PMA), implicating a PKC-dependent mechanism. Single-channel analysis indicates that SP acts through reduction of channel mean open-time (cmot): GABAA cmot being reduced by approximately 60% by SP (P≤0.05 ANOVA, Bonferroni). These data suggest that tachykinins mediate their pressor activity by increasing the excitability of spinally-projecting neurons and identifies NK1 receptors as potential targets for therapeutic modulation of the cardiovascular system.


Key Words: cardiovascular control • GABA • substance P